Summit Therapeutics Reports Partner's Positive Phase III OS Results

What Happened

• On September 2, 2026, Summit Therapeutics (SMMT) issued a press release reporting that its partner Akeso announced positive overall survival (OS) results from the randomized, double‑blind Phase III HARMONi-2 study.
• HARMONi-2 compared ivonescimab monotherapy to pembrolizumab monotherapy in patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) whose tumors express PD‑L1; the preplanned OS analysis (a secondary endpoint) showed a statistically significant improvement for ivonescimab.
• Akeso sponsored and exclusively generated, managed, and analyzed the data; the results are scheduled for presentation at an upcoming medical conference. Summit filed the Form 8-K on September 3, 2026 and attached the press release as Exhibit 99.1.

Key Details

• Date of press release: September 2, 2026; Form 8-K filed September 3, 2026.
• Study: Phase III HARMONi-2, randomized, double‑blind, single‑region multi‑center (China).
• Comparator: ivonescimab monotherapy vs. pembrolizumab monotherapy.
• Result: Statistically significant improvement in overall survival (OS) for ivonescimab in a preplanned analysis (OS was a secondary endpoint).
• Data ownership/analysis: All relevant data were generated, managed, and analyzed by Akeso.

Why It Matters

• A statistically significant OS benefit in a Phase III study is an important clinical milestone for ivonescimab and may affect the drug’s regulatory and commercial prospects—especially in the China region where the study was conducted.
• For investors, the filing conveys positive clinical news from Summit’s partner but does not itself provide detailed data, regulatory actions, or financial impacts; full trial details will be important when Akeso presents the data.
• Summit’s 8-K reports the event (press release) only; no earnings, financing, or corporate governance changes were disclosed in this filing.